We use cookies on our site to track usage and preferences. Learn more

Qkine and Enantis sign a licensing deal to bring hyperstable FGF2-STAB® to the global stem cell community

  • Date 2 Aug 2021

Cambridge University spin-out, Qkine, and Enantis, a biotechnology spin-off company from Masaryk University, have concluded a licensing deal for Qkine to use Enantis’s patented FGF2-STAB® technology globally and develop new product-lines based on the unique biochemical properties of the protein.

FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. This optimised form of the protein does not degrade in culture media leading to a range of applications in enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.

Read more

Join an ambitious, supportive community of world-class scientists, engineers and entrepreneurs

Read more